The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.
Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...